Titration schedule (investigational)
Retatrutide titration schedule
Retatrutide has no FDA label and no approved dose, so there is no official titration schedule. What exists is the dose escalation researchers used in its published Phase 2 obesity trial. We show it here for reference, clearly labeled as research.
Last updated 2026-08-24
Investigational
Retatrutide is not approved by the FDA or any regulator for any use. There is no prescribing label and no approved dose. The schedule below is the dose escalation used in a published clinical trial, shown for reference only. It is not a recommendation and not a protocol to follow.
Because there is no approved product, everything below comes from a clinical trial, not a prescribing schedule. The trial assigned participants to target maintenance doses and escalated them from a low starting dose to reduce side effects. The exact week each step happened is not stated in the openly available trial summary.
Phase 2 obesity trial (NCT04881760), once weekly for 48 weeks
Trial scheduleRandomized trial dose arms, adults with obesity or overweight
| Step | Dose | Notes |
|---|---|---|
| 1 mg arm | 1 mg | Flat dose, no escalation |
| 4 mg arm | Started at 2 mg or 4 mg, escalated to 4 mg | Two starting-dose sub-arms |
| 8 mg arm | Started at 2 mg or 4 mg, escalated to 8 mg | Via intermediate steps |
| 12 mg arm | Started at 2 mg, escalated 2 to 4 to 8 to 12 mg | Highest dose tested |
Maximum: 12 mg once weekly was the highest dose studied in this trial. There is no approved maximum because retatrutide is not approved.
The trial escalated from a low starting dose to a target maintenance dose to improve tolerability. The published abstract and the ClinicalTrials.gov record give the starting doses and target arms but do not state the exact week each escalation step occurred.
Using this as a tracker template
- Treat this as trial documentation, not a plan. There is no approved retatrutide product and no prescribing schedule to track against.
- If you are following retatrutide research, the useful record is the source trial itself, cited below, and its Phase 3 program now underway.
- For an approved GLP-1 with a real titration schedule, see the semaglutide and tirzepatide pages.
Questions people ask
Is retatrutide FDA approved?
No. As of this writing retatrutide is investigational - it has completed Phase 2 trials and is in Phase 3 development, but it is not approved by the FDA or any regulator for any use, and there is no prescribing label. Any dose figure comes from a clinical trial, not an approved schedule.
What doses were tested in the retatrutide trial?
The Phase 2 obesity trial tested weekly doses of 1, 4, 8, and 12 mg, with the higher-dose arms starting lower (2 or 4 mg) and escalating to the target. The 12 mg arm produced the largest average weight change, about -24.2 percent at 48 weeks, versus -2.1 percent for placebo. These are trial averages, not a promise of individual results.
How fast was retatrutide escalated in the trial?
The trial escalated from a low starting dose (2 or 4 mg) up to the assigned target over the study, but the exact week markers for each step are not stated in the openly available PubMed abstract or the ClinicalTrials.gov record, so we do not report a week-by-week schedule for it.
Sources
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial - Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315.Randomized to retatrutide 1, 4 (initial 2 or 4 mg), 8 (initial 2 or 4 mg), or 12 mg (initial 2 mg) or placebo once weekly for 48 weeks; 12 mg produced -24.2% mean weight change vs -2.1% placebo
- [2]A Study of Retatrutide (LY3437943) in Participants With Obesity - ClinicalTrials.gov NCT04881760Trial record confirming the dose arms and starting-dose stratification (2 mg or 4 mg initial, escalating to 4, 8, or 12 mg target) for the Phase 2 obesity study
Related
This page is educational information, not medical advice. GLP-1 medications are prescription drugs; dosing, escalation, and any combination with other compounds are decisions for you and a licensed prescriber, based on the actual product you hold and your own health. Figures here describe published FDA labels and clinical trials - they are not a recommendation to take any dose. Compounded and research-grade products can differ in concentration and purity from the approved versions these schedules were written for.